Jingjing Qu1, Min Li1, Wen Zhong1, Chengping Hu1. 1. Department of Respiratory Medicine, Xiangya Hospital, Central South University Changsha 410008, Hunan, China.
Abstract
BACKGROUND: miRNAs have been participated in human carcinogenesis as tumor oncogenes or suppressors, and have a prognostic significant for patients with cancers. In recent years, miR-25 was found associated with clinical value of cancerous patients. Meanwhile the miR-25 showed a different expression in related studies. Therefore, we summarize the results from a variety of studies using a meta-analysis, in order to explain the prognostic value of miR-25 in many human cancers. METHODS: The articles were retrieved from the on-line databases, PubMed, EMBASE and CNKI. We extracted and estimated the hazard ratios (HRs) for overall survival (OS), which compared the high and low expression levels of miR-25 in patients with a different of cancers. Pooled HRs and 95% confidence intervals (CIs) were calculated. RESULTS: Eight studies of 868 patients were selected into the final meta-analysis after a strict filtering and qualifying process. Fixed model or random model method was chosen depending on the heterogeneity between the studies. For OS, higher miR-25 expression could significantly predict worse outcome with the pooled HR of 2.434 (95% CI 1.330-3.539, P=0.000). The subgroup analysis showed that high expressed miR-25 could worsen OS in Chinese patients with pooled HR of 1.895 (95% CI 1.096-2.693, P=0.007). The sensitive analysis showed that removing the document one by one, there no obvious change of HR of 0.823 (95% CI 0.385-1.260). No bias existed in the group. CONCLUSION: Our study indicates that high expression level of miR-25 corresponds with poor survival in cancerous patients, and the expression of miR-25 could be a promising prognostic biomarker in the future.
BACKGROUND: miRNAs have been participated in humancarcinogenesis as tumor oncogenes or suppressors, and have a prognostic significant for patients with cancers. In recent years, miR-25 was found associated with clinical value of cancerouspatients. Meanwhile the miR-25 showed a different expression in related studies. Therefore, we summarize the results from a variety of studies using a meta-analysis, in order to explain the prognostic value of miR-25 in many humancancers. METHODS: The articles were retrieved from the on-line databases, PubMed, EMBASE and CNKI. We extracted and estimated the hazard ratios (HRs) for overall survival (OS), which compared the high and low expression levels of miR-25 in patients with a different of cancers. Pooled HRs and 95% confidence intervals (CIs) were calculated. RESULTS: Eight studies of 868 patients were selected into the final meta-analysis after a strict filtering and qualifying process. Fixed model or random model method was chosen depending on the heterogeneity between the studies. For OS, higher miR-25 expression could significantly predict worse outcome with the pooled HR of 2.434 (95% CI 1.330-3.539, P=0.000). The subgroup analysis showed that high expressed miR-25 could worsen OS in Chinese patients with pooled HR of 1.895 (95% CI 1.096-2.693, P=0.007). The sensitive analysis showed that removing the document one by one, there no obvious change of HR of 0.823 (95% CI 0.385-1.260). No bias existed in the group. CONCLUSION: Our study indicates that high expression level of miR-25 corresponds with poor survival in cancerouspatients, and the expression of miR-25 could be a promising prognostic biomarker in the future.
Authors: D F Stroup; J A Berlin; S C Morton; I Olkin; G D Williamson; D Rennie; D Moher; B J Becker; T A Sipe; S B Thacker Journal: JAMA Date: 2000-04-19 Impact factor: 56.272
Authors: Jumei Zhou; Jing Wang; Shengqi Wu; Suyu Zhu; Sai Wang; Huijun Zhou; Xiaoqing Tian; Ning Tang; Shaolin Nie Journal: Int J Mol Med Date: 2014-08-19 Impact factor: 4.101
Authors: Yang Li; Weiqi Tan; Thomas W L Neo; Myat O Aung; Shanthi Wasser; Seng G Lim; Theresa M C Tan Journal: Cancer Sci Date: 2009-04-15 Impact factor: 6.716